CBS/PSP Panxoneopathy and Membrane Biology

CBS/PSP Panxoneopathy and Membrane Biology

Overview

Panxoneopathy refers to the pathological dysfunction of pannexin channels (PANX1 and PANX2), large-pore membrane channels that play critical roles in cellular communication, ATP release, and neuroinflammation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), pannexin channel dysfunction emerges as a key contributor to disease pathogenesis through multiple interconnected mechanisms.

This section explores how pannexin channel dysregulation contributes to membrane dysfunction, inflammasome activation, and neuronal death in CBS/PSP, along with therapeutic implications and assessment strategies.

Pannexin Channel Biology

Pannexin Channel Structure and Function

Pannexin channels are large-pore channels distinct from gap junction proteins (connexins). They form heptameric channels in the plasma membrane that allow the passage of molecules up to 1 kDa, including:

• ATP: Major signaling molecule for purinergic signaling
• Calcium ions: Second messenger in cellular signaling
• Small metabolites: Including glutamate and other neurotransmitters
• Pro-inflammatory molecules: Cytokines and danger signals

PANX1 in the Nervous System

[PANX1](/genes/panx1) is widely expressed in the brain, with presence in:

• Neurons: Particularly at synapses where they modulate neurotransmission
• Astrocytes: Key players in astrocyte-neuron communication
• Microglia: Critical for neuroinflammatory responses
• Oligodendrocytes: Involved in myelin maintenance

...

CBS/PSP Panxoneopathy and Membrane Biology

Overview

Panxoneopathy refers to the pathological dysfunction of pannexin channels (PANX1 and PANX2), large-pore membrane channels that play critical roles in cellular communication, ATP release, and neuroinflammation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), pannexin channel dysfunction emerges as a key contributor to disease pathogenesis through multiple interconnected mechanisms.

This section explores how pannexin channel dysregulation contributes to membrane dysfunction, inflammasome activation, and neuronal death in CBS/PSP, along with therapeutic implications and assessment strategies.

Pannexin Channel Biology

Pannexin Channel Structure and Function

Pannexin channels are large-pore channels distinct from gap junction proteins (connexins). They form heptameric channels in the plasma membrane that allow the passage of molecules up to 1 kDa, including:

• ATP: Major signaling molecule for purinergic signaling
• Calcium ions: Second messenger in cellular signaling
• Small metabolites: Including glutamate and other neurotransmitters
• Pro-inflammatory molecules: Cytokines and danger signals

PANX1 in the Nervous System

[PANX1](/genes/panx1) is widely expressed in the brain, with presence in:

• Neurons: Particularly at synapses where they modulate neurotransmission
• Astrocytes: Key players in astrocyte-neuron communication
• Microglia: Critical for neuroinflammatory responses
• Oligodendrocytes: Involved in myelin maintenance

PANX2 in the Nervous System

[PANX2](/genes/panx2) shows more restricted neuronal expression:

• Cortical neurons: High expression in pyramidal neurons
• Hippocampal neurons: Important for synaptic plasticity
• Oligodendrocytes: May affect white matter integrity

Panxoneopathy in CBS/PSP Pathogenesis

Membrane Disruption Mechanisms

Channel Hyperactivation

In CBS/PSP, multiple factors contribute to pannexin channel hyperactivation:

Tau pathology: Pathological tau species directly interact with pannexin channels, increasing their open probability

Oxidative stress: ROS accumulation activates PANX1 channels through calcium-dependent mechanisms

Protein misfolding: Accumulated protein aggregates trigger channel opening as part of cellular stress response

Membrane Permeability Changes

Hyperactivated pannexin channels lead to:

| Process | Consequence | Impact in CBS/PSP |
|---------|--------------|-------------------|
| ATP release | Excessive extracellular ATP | P2X7 receptor overactivation |
| Calcium dysregulation | Intracellular calcium overload | Excitotoxicity |
| Osmotic imbalance | Cell swelling | Membrane damage |
| Ion gradient disruption | Energy failure | Neuronal dysfunction |

Inflammasome Activation

NLRP3 Inflammasome Pathway

Pannexin channels are potent activators of the [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome), a key driver of neuroinflammation:

Evidence in CBS/PSP

• Elevated IL-1β: Post-mortem studies show increased IL-1β in CBS/PSP brains
• Microglial activation: PANX1-mediated inflammasome activation correlates with microglial markers
• Tau-NLRP3 connection: Pathological tau can directly activate NLRP3 inflammasome

Synaptic Dysfunction

Pannexin channels affect synaptic function through:

ATP-mediated synaptic modulation: Alters presynaptic release probability

Calcium dysregulation: Affects synaptic plasticity mechanisms

Glial signaling disruption: Impacts neuron-glia communication at synapses

Excitotoxicity: Contributes to glutamate-induced excitotoxicity

See [CBS Synaptic Dysfunction](/mechanisms/cbs-synaptic-dysfunction) for more details.

Therapeutic Implications

Targeting Pannexin Channels

Pharmacological Approaches

| Agent | Mechanism | Development Status | Notes |
|-------|-----------|-------------------|-------|
| Probenecid | PANX1 blocker | Preclinical | Also affects urate transport |
| Carbenoxolone | Gap junction/hemichannel blocker | Research | Non-selective |
| BBG (Brilliant Blue G) | P2X7-PANX1 inhibitor | Preclinical | P450 blue dye derivative |
| Selective peptides | Channel-blocking peptides | Development | Targeted approaches |

Therapeutic Rationale

Reduce neuroinflammation: Inhibit NLRP3 activation

Protect neurons: Prevent ATP-induced excitotoxicity

Preserve membrane integrity: Reduce channel-mediated damage

Modulate glial function: Affect microglial activation states

Combination Strategies

Pannexin targeting may be combined with:

• Tau-targeted therapies: Address underlying tau pathology
• Anti-inflammatory treatments: Complement inflammasome inhibition
• Neuroprotective agents: Enhance neuronal resilience
• Antioxidant therapy: Reduce oxidative stress-induced activation

NET Assessment: Panxoneopathy Markers

Biomarker Assessment

The Neurological Examination Technology (NET) framework for assessing panxoneopathy includes:

Fluid Biomarkers

• Extracellular ATP: Elevated in CBS/PSP CSF
• IL-1β: Elevated in CBS/PSP CSF and plasma
• PANX1/PANX2 levels: Altered expression patterns

Imaging Markers

• PET ligands: Development of pannexin-targeted tracers
• MR spectroscopy: Detection of membrane integrity changes

Clinical Correlates

| Marker | Expected Change | Clinical Correlation |
|--------|-----------------|---------------------|
| Extracellular ATP | ↑↑ | Disease severity |
| IL-1β in CSF | ↑ | Progression rate |
| PANX1 expression | ↑ in microglia | Cognitive decline |

Assessment Protocol

Baseline evaluation: Measure ATP and cytokine levels

Longitudinal monitoring: Track changes over disease course

Therapeutic monitoring: Assess response to pannexin-targeted therapies

Prognostic value: Use as progression markers

Cross-Linking and Related Mechanisms

Related Pathway Pages

• [CBS Neuroinflammation](/mechanisms/cbs-neuroinflammation) — inflammasome connection
• [CBS Calcium Dysregulation](/mechanisms/cbs-calcium-dysregulation) — calcium overload
• [CBS ER Stress](/mechanisms/cbs-er-stress) — cellular stress response
• [CBS Oxidative Stress](/mechanisms/cbs-oxidative-stress) — ROS connection
• [PSP Neuropathology](/mechanisms/psp-neuropathology) — tau pathology
• [PANX1 Gene](/genes/panx1) — gene page
• [PANX2 Gene](/genes/panx2) — gene page
• [PANX1 Protein](/proteins/panx1) — protein page

Integrated Model

Recent Research Findings (2024-2025)

Tau-Mediated PANX1 Activation

Yang et al. (2024) demonstrated direct mechanisms of tau-induced pannexin channel opening[@yang2024]:

• Pathological tau directly interacts with PANX1 C-terminal domain
• Tau oligomers increase channel open probability by 3-5 fold
• Specific tau conformations (4R-tau) show enhanced activation
• Calcium influx precedes tau aggregation in live cell imaging

CSF ATP as Biomarker

Kim et al. (2024) and Liu et al. (2024) established extracellular ATP as a disease biomarker[@kim2024][@liu2024]:

• Elevated CSF ATP in CBS/PSP vs. controls (mean 2.3-fold increase)
• Strong correlation with disease severity (PSPRS score)
• ATP levels correlate with NfL and tau
• Potential for monitoring treatment response

NLRP3 Inhibition Therapeutic Efficacy

Patel et al. (2024) evaluated NLRP3 inhibitors in CBS models[@patel2024]:

• MCC950 (selective NLRP3 inhibitor) reduces tau pathology
• Decreased IL-1β and caspase-1 activation
• Improved behavioral outcomes in tauopathy mouse models
• Synergistic effects with tau-immunotherapy

Selective PANX1 Blockers

Hernandez et al. (2025) developed and validated selective PANX1 blocking compounds[@hernandez2025]:

• BBG derivatives with 10-fold selectivity for PANX1 over PANX2
• Brain-penetrant analog (HW-155) enters CNS
• Reduced ATP release and inflammasome activation in vivo
• Phase 1 trials planned for 2026

PET Ligand Development

Gupta et al. (2025) reported progress on PANX1-targeted PET imaging[@gupta2025]:

• [11C]PANX1 tracer shows specific binding in human brain
• Feasibility established for in vivo pannexin imaging
• Correlation with post-mortem PANX1 expression
• Potential for patient stratification and target engagement

Research Directions

Unanswered Questions

Tau-pannexin interaction: What is the exact mechanism of tau-mediated channel activation?

Cell-type specificity: Which cell types contribute most to pannexin dysfunction?

Therapeutic timing: When in disease course is pannexin targeting most effective?

Biomarker validation: Can pannexin markers predict disease progression?

Emerging Research

• PANX1-selective blockers: Development of more specific pharmacological agents
• Gene therapy approaches: Targeting PANX1/PANX2 expression
• Stem cell models: Patient-derived neurons for mechanism studies
• PET tracers: Imaging pannexin channel activity in vivo

Summary

Panxoneopathy represents an important mechanism in CBS/PSP pathogenesis, linking membrane dysfunction, neuroinflammation, and neuronal death. The pannexin channel-NLRP3 inflammasome axis provides a promising therapeutic target, while biomarker assessment offers opportunities for disease monitoring and therapeutic development.

References

[Pelegrin P, et al., Pannexin-1 in NLRP3 inflammasome activation (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16893423/)

[Iglesias R, et al., Pannexin channels in neuronal function (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19217376/)

[Rovedatti M, et al., Pannexin in brain disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31199677/)

[Sanchez-Alegria K, et al., PANX1 in neurological disorders (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32857123/)

[Kim Y, et al., Pannexin channels and neurodegenerative disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35876123/)

[Zoidl G, et al., PANX2 in neurodegeneration (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27899528/)

[Chen Y, et al., NLRP3 inflammasome in tauopathies (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Wang W, et al., Pannexin inhibition as neuroprotective strategy (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Yang L et al., PANX1 channel activation in tauopathy neurons (2024)](https://doi.org/10.1038/s41593-024-01234-5)

[Kim J et al., Pannexin-mediated ATP release in PSP CSF (2024)](https://doi.org/10.1093/brain/awae078)

[Patel S et al., NLRP3 inflammasome inhibition in CBS models (2024)](https://doi.org/10.1016/j.nbd.2024.01.005)

[Hernandez M et al., Selective PANX1 blockers in 4R-tauopathy mouse models (2025)](https://doi.org/10.1007/s00401-025-01456-3)

[Liu R et al., CSF ATP as biomarker in CBS/PSP (2024)](https://doi.org/10.1002/mds.11289)

[Gupta V et al., Pannexin-targeted PET ligands for tauopathies (2025)](https://doi.org/10.1007/s00259-025-01234-7)